Luis E. Aguirre, MD, MPH

Luis E. Aguirre, MD, MPH (c) is a Medical Oncologist and Academic Hematologist joining the Malignant Hematology Division at Yale Cancer Center and Yale School of Medicine as Assistant Professor of Medicine. His academic career is shaped by a dual focus: the design of robust retrospective research supported by scalable data infrastructure, and the development and implementation of early-phase clinical trials. He is particularly focused on integrating correlative science into clinical trial design to better understand disease biology, treatment resistance, and patient-specific factors that influence response. Through this approach, Dr. Aguirre aims to identify novel biomarkers and therapeutic targets that can inform more personalized and effective treatment strategies.

His research has concentrated on elucidating the pathodynamics—the mechanisms driving disease initiation and progression—as well as the biological and clinico-molecular features of myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML), and myeloproliferative neoplasms (MPNs). These investigations not only deepen understanding of disease heterogeneity but also help refine risk stratification and guide treatment selection. To support and enhance these efforts, he is currently completing a Master of Public Health (MPH) in Clinical Effectiveness, with a focus on Applied Clinical Research Methods, at the Harvard T.H. Chan School of Public Health, with additional specialization in biostatistics, clinical epidemiology, and health policy.

A key area of Dr. Aguirre’s expertise lies in building and expanding clinical data infrastructure to support hypothesis-driven research. At the H. Lee Moffitt Cancer Center in Tampa, FL, and the Dana-Farber Cancer Institute/Brigham and Women’s Hospital/Harvard Medical School, he contributed to the establishment of integrated repositories that include detailed clinical, genomic, and therapeutic data for patients with myeloid malignancies. These datasets have served as the foundation for studies that:

• Expand clinical datasets by building repositories for MDS, CMML, AML, and related disorders, enabling analyses of treatment patterns and disease progression.
• Leverage real-world data to conduct retrospective studies identifying prognostic biomarkers, evaluating therapeutic strategies, and assessing treatment effectiveness.
• Foster multidisciplinary collaborations with experts in bioinformatics, pathology, and translational science to construct predictive models that inform clinical decision-making and individualize patient care.

Dr. Aguirre completed his residency in Internal Medicine at the University of Miami, followed by a fellowship in Hematology and Medical Oncology at the H. Lee Moffitt Cancer Center in Tampa. He subsequently pursued advanced clinical and research training as the Foley Family Fellow in Leukemia at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital/Harvard Medical School, where he cared for highly complex patients with acute leukemias and related myeloid neoplasms while leading investigator-initiated clinical trials and translational research initiatives.

Dr. Aguirre’s academic portfolio sits at the intersection of clinical trials and data science. He aims to establish scalable research infrastructure that integrates real-world clinical data with genomic, therapeutic, and outcomes-based insights. Through this integrated framework, he seeks to refine disease classification, guide treatment algorithms, and ultimately improve the lives of patients with hematologic malignancies.

Nationally, Dr. Aguirre was selected to the American Society of Hematology (ASH) Clinical Research Training Institute (CRTI), one of the most competitive research training programs in hematology, highlighting his promise as a future leader in clinical investigation. He also served as the Hematology/Oncology Fellow Liaison to the Board of Directors of the Florida Society of Clinical Oncology (FLASCO), reflecting early leadership in professional society governance. His research has been recognized with multiple honors, including Merit and Young Investigator Awards from the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the European Hematology Association (EHA), the Society of Hematologic Oncology (SOHO), and recognition by the American College of Physicians (ACP) as a Young Achiever.

Dr. Aguirre is an active member of the American College of Physicians (ACP), the American Association for Cancer Research (AACR), the American Society of Hematology (ASH), and the American Society of Clinical Oncology (ASCO). This rare combination of high-level clinical acumen, deep disease-specific expertise, rigorous biostatistical training, and leadership in clinical trial development distinguishes him among his peers. His ability to bridge advanced clinical practice with sophisticated, data-driven research positions him as a uniquely valuable asset to collaborative networks, research consortia, and academic institutions committed to advancing the care of patients with myeloid malignancies. His trajectory exemplifies the scarce profile of a physician-scientist who can not only provide expert bedside care but also independently design and execute the next generation of clinical research.